LIVONIA, Mich., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today announced that Mina Sooch, President and Chief Executive Officer, will present corporate updates at the Piper Jaffray 28 th Annual Healthcare Conference and the LD Micro Main Event conference. Gemphire's product candidate, gemcabene, is a novel, once-daily, oral therapy with three separate Phase 2b clinical trials in dyslipidemic patients with HoFH, HeFH/ASCVD and SHTG, scheduled to be completed in 2017. Piper Jaffray Healthcare Conference Presentation Details: Date: Tuesday, November 29Time: 1:30pm Eastern TimeLocation: The Lotte New York Palace Hotel, Kennedy 1, 4 th Floor, New York, NY LD Micro Main Event Presentation Details: Date: Wednesday, December 7Time: 8:30am Pacific TimeLocation: Luxe Sunset Boulevard Hotel, Los Angeles, CA The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire's website at http://ir.gemphire.com. About GemcabeneGemphire's product candidate, gemcabene (CI-1027), is a novel, once-daily, oral therapy that may be suitable for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statins. Gemcabene's mechanism of action is designed to enhance the clearance of very low-density lipoproteins (VLDLs) in the plasma and inhibit the production of cholesterol and triglycerides in the liver. The combined effect for these mechanisms has been observed to result in a reduction of plasma VLDL-C, LDL-C, and triglycerides, as well as markedly lowering C-reactive protein. Gemcabene is liver-directed and reduces apoC-III mRNA and plasma levels and may also inhibit acetyl-CoA carboxylase (ACC) which has applications in NASH/NAFLD. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895 subjects across 18 Phase 1 and Phase 2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability.